bioRxivImmunologyPreprint
Enabling MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance without chemotherapy or radiation
B. George, K. S. Kao, A. Chen, A. C. Le, A. Chhabra, C. Burnett, K. M. Loh, J. A. Shizuru, I. Weissman
Abstract
Hematopoietic stem cell (HSC) transplantation can replace diseased blood systems with a healthy one, thereby treating or curing genetic blood and immune disorders including autoimmune diseases and immunodeficiencies. However, toxic chemotherapy or radiation is necessary to ablate an animals existing blood system prior to HSC transplantation, leading to significant morbidity. To accomplish safer blood-system replacement we developed a combination of six monoclonal antibodies to safely and specifically deplete the HSCs, T cells and NK cells of immune-competent mice. Remarkably, immunologically-foreign (allogeneic) HSCs mismatched at half or all the MHC genes could engraft these antibody-treated mice, generating donor blood systems that stably co-existed with host blood cells. These chimeric immune systems were immunologically tolerant to heart tissue from the HSC donor, providing a safe platform for HSC transplantation as a means to solid organ transplantation. The ability to transplant MHC-mismatched HSCs without chemotherapy or radiation has significant ramifications for regenerative medicine.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Modeling competitive transplantation using HLA-mismatched human hematopoietic stem cells
Abdullahi Mobolaji Idowu, James P. Ropa, Stephanie N. Hurwitz·Stem Cell Research & TherapyPeer-reviewed·Oct 27, 2026
- Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation
S. P. Persaud, J. K. Ritchey, … J. F. DiPersio·bioRxiv·Oct 2, 2020
- Stable colony stimulating factor 1 fusion protein treatment increases HSC pool and enhances their mobilisation in mice.
S. Kaur, A. Sehgal, … A. R. Pettit·bioRxiv·Sep 13, 2020
- After migration into blood circulation, hematopoietic stem cells can stably self-renew and maintain bone marrow while being skewed toward myeloid lineage when submitted to serial transplantation.
Y. Even, L. Yi, … F. M. Rossi·bioRxiv·Mar 4, 2021
- Donor-Targeted Anti-HLA-A2 Antibody Shows Nanogram-Level Efficacy in a Novel GVHD Mouse Model
Kouta Niizuma, Alyssa H Chang, … Yusuke Nakauchi·Blood AdvancesPeer-reviewed·Jul 21, 2026
- Targeting Anti-HLA Class I and II Antibodies with CAR-B Cell Therapy: A Novel Strategy to Mitigate Graft Rejection and Platelet Refractoriness
Varun Kesherwani·bioRxiv·Feb 20, 2025